Biosimilar Antibodies

APX-007 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the IL-6 receptor alpha (IL-6Ra/CD126). This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Lemalesomab (IMMU-MN3) is a monoclonal antibody derived from mouse IgG1, specifically designed as a Fab' fragment targeting NCA-90. This antibody is utilized primarily in the study of inflammation, infectious lesions, and for the imaging of infections in research settings. Its specificity for NCA-90 makes it a valuable tool for detailed investigations into cellular processes associated with immune responses and microbial infection.

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα). By inhibiting signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), this antibody has demonstrated significant efficacy in ameliorating the symptoms of moderate-to-severe atopic dermatitis. This specificity makes it a valuable tool for research into the pathophysiology and treatment of allergic and inflammatory diseases.

Aducanumab (BIIB037) is a human monoclonal antibody designed to selectively target aggregated forms of amyloid-beta (Aβ), a key pathological marker in Alzheimer’s disease (AD). Demonstrating effective penetration into brain tissue, Aducanumab is extensively utilized in the research of Alzheimer's disease mechanisms and potential therapies. This antibody is pivotal for studies focusing on the pathogenesis and treatment strategies of AD, providing essential insights into amyloid-beta dynamics and clearance in neural environments.

NGM-120 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Glial Cell line-Derived Neurotrophic Factor Family Receptor Alpha Like (GFRAL). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145.7 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.

Semzuvolimab is a humanized IgG1κ monoclonal antibody specifically designed to target the p55 T cell surface antigen T4/Leu-3, commonly known as CD4. This antibody has demonstrated capabilities in neutralizing HIV infections and shows potential in inhibiting HIV infections that are stable under highly active antiretroviral therapy (HAART). Semzuvolimab offers significant utility in research focused on the immunological aspects of HIV management and therapy development.

Etentamig is a bispecific T-cell engager (BiTE) targeting both B-cell maturation antigen (BCMA) and the CD3 complex on T cells. This dual specificity enables Etentamig to simultaneously inhibit BCMA activity and activate the CD3 signaling pathway in T cells. It is primarily utilized in research focused on multiple myeloma and immunoglobulin light chain amyloidosis, with potential applications in exploring its effects on cardiovascular diseases. This makes Etentamig a valuable tool for advancing understanding of disease mechanisms and therapeutic strategies in these areas.

Zadoprubart is a humanized IgG4κ monoclonal antibody specifically targeting BTLA (B and T Lymphocyte Attenuator). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and control recommendation ensure precise targeting and accurate data interpretation in research applications focusing on immune modulation.

Omodenbamab is a human monoclonal antibody that targets Staphylococcal protein A (SpA), a critical component of the Staphylococcus aureus cell wall. With a dissociation constant (KD) of 0.0467 nM, this antibody demonstrates high affinity for SpA, effectively disrupting a major S. aureus immune evasion strategy. Omodenbamab is primarily utilized in the investigation of S. aureus bloodstream infections, providing a valuable tool for research in microbial pathogenesis and immune response mechanisms.

The Anti-TNFSF2 / TNFa (ESBA 105) antibody specifically targets Tumor Necrosis Factor (TNF), a critical cytokine involved in systemic inflammation and the acute phase response. This antibody is characterized by its efficient intraocular penetration, reaching both the anterior and posterior regions of the eye, making it particularly useful in research studies focused on ocular diseases and inflammatory responses within the eye.

RG-6125 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CDH11, also known as Cadherin-11. This antibody is comprised of a human IgG2 type heavy chain and a human kappa (huκ) type light chain, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended.

Cenzestotug is a monoclonal antibody that specifically targets the human Tumor Necrosis Factor Receptor Superfamily Member 4 (TNFRSF4). By binding to TNFRSF4, Cenzestotug activates key immune cells, demonstrating potent immunostimulatory and antitumor properties. This antibody holds significant potential for research in cancer immunotherapy, providing a valuable tool for investigating the modulation of immune responses in oncological studies.

Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody designed to target LIGHT, a cytokine related to tumor necrosis factor (TNF) identified as TNFSF14. This cytokine is critically involved in the pathogenesis of acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS), particularly noted in COVID-19 cases. The therapeutic potential of Quisovalimab extends to its application in research focused on COVID-19-induced ARDS and related inflammatory conditions, providing a valuable tool for studies aimed at understanding and mitigating cytokine-mediated diseases.

Frunevetmab (NV-02) is a felinized monoclonal antibody targeting nerve growth factor (NGF) with a dissociation constant (Kd) of 20 pM, indicating high affinity for its antigen. This antibody has been shown to effectively reduce osteoarthritis-related pain in feline models, making it a valuable tool for research into pain management and degenerative joint diseases in cats.

Sifalimumab (MEDI-545) is a monoclonal antibody that targets and neutralizes multiple subtypes of interferon-alpha (IFNα), a key cytokine involved in the pathogenesis of autoimmune disorders. By binding to IFNα, Sifalimumab effectively suppresses abnormal immune responses. This antibody is particularly relevant for research into systemic lupus erythematosus (SLE), providing a valuable tool for investigating the role of IFNα in SLE pathophysiology and for exploring potential therapeutic interventions.

Imaprelimab (PRX-003) is a humanized IgG1κ monoclonal antibody targeting the melanoma cell adhesion molecule (MCAM). Classified as an antineoplastic agent, it is designed to interfere with MCAM-mediated processes, potentially inhibiting tumor growth and metastasis in melanoma and other cancers expressing MCAM. This antibody is utilized primarily in research focused on cancer biology and therapeutic development.

Anbenitamab (KN-026) is a bispecific antibody engineered to target extracellular domains II and IV of human HER2, effectively blocking both ligand-dependent and ligand-independent signaling pathways associated with this receptor. The inclusion of the IgG1 Fc fragment enhances its interaction with FcRγIIIa, facilitating robust antibody-dependent cell-mediated cytotoxicity (ADCC) and effectively inhibiting tumor cell proliferation. This antibody is primarily researched for its therapeutic potential in HER2-positive metastatic breast cancer (MBC).

The Anti-B7-H4/VTCN1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the B7-H4/VTCN1 antigen, a protein implicated in the regulation of immune response. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a predicted molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. This product is ideal for use in research applications focusing on immune modulation and cancer immunotherapy.

Clesitamig is a humanized antibody designed to specifically target DLL3 (Delta-like ligand 3). This antibody features a variable light chain (V-κ) and a gamma 1 heavy chain (G4CH1-G1h-H-γ1), configured in a structurally optimized format to ensure high specificity and affinity for DLL3. Clesitamig is ideal for research focused on the role of DLL3 in cancer pathogenesis and therapy, particularly in the context of small cell lung cancer and other neuroendocrine tumors where DLL3 expression is prevalent.

Tidutamab (XmAb-18087) is a humanized, affinity-optimized bispecific antibody designed to target both the somatostatin receptor 2 (SSTR2) and the CD3 epsilon subunit of the T-cell receptor. This antibody features a complete Fc domain, which enhances its stability and prolongs its serum half-life. Tidutamab facilitates the elimination of SSTR2-expressing tumor cells through the mechanism of redirected T-cell-mediated cytotoxicity (RTcC), offering a targeted approach in cancer immunotherapy.

Sacituzumab is a humanized IgG1 monoclonal antibody that specifically targets Trophoblast cell surface antigen 2 (TROP2). This antibody binds to the linear epitopes of the TROP2 protein. Although Sacituzumab alone does not exhibit antitumor effects or inhibit the function of TROP2 during tumor metastasis, it serves as a foundational component for the development of antibody-drug conjugates (ADCs). A notable application of Sacituzumab is its conjugation with the cytotoxic drug, govitecan, to form Sacituzumab govitecan. This conjugate has demonstrated utility in the treatment of triple-negative breast cancer, highlighting its significant potential in therapeutic applications targeting this challenging oncological condition.

Citatuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target EpCAM (Epithelial Cell Adhesion Molecule), also known as TROP1 or CD326. This antibody comprises a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 145.4 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. Citatuzumab is applicable in research focused on cancer cell biology, particularly in studies investigating epithelial cell adhesion and metastasis.

Emapalumab (NI-0501) is a human monoclonal IgG1 antibody designed for the noncompetitive inhibition of interferon gamma (IFN-γ). It exhibits high binding affinity, with a dissociation constant (Kd) of 1.4 pM, to both free IFN-γ and IFN-γ that is bound to its receptor. This antibody is particularly useful in the study of hemophagocytic lymphohistiocytosis (HLH), providing a critical tool for research into the pathophysiology and potential therapeutic interventions for this condition.

Ebdarokimab (AK101) is a humanized IgG1-κ monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody is engineered for high specificity and affinity in targeting its designated antigens, ensuring effective application in therapeutic research.

Bivatuzumab (BIWA 4), a humanized monoclonal antibody, targets the CD44v6 isoform, a variant of the CD44 standard form. This antibody has been specifically developed for its potential role in targeting CD44v6, which is implicated in the progression of various sarcomas. Bivatuzumab is utilized in research focusing on chimeric antigen receptor (CAR)-redirected cytokine-induced killer (CIK) cells, providing a promising therapeutic approach for sarcoma treatment.

Leronlimab (PRO 140) is a humanized IgG4 monoclonal antibody targeting CCR5, a critical receptor involved in the entry of HIV-1 into cells and in the mediation of inflammatory processes. This antibody effectively inhibits HIV-1 viral entry and has demonstrated potential in reducing lung metastasis in mouse tumor models. Leronlimab is applicable for research in various fields including HIV, nonalcoholic steatohepatitis (NASH), and cancer, providing a versatile tool for investigating the role of CCR5 in disease progression and therapy.

Imzokitug is a humanized IgG1κ monoclonal antibody specifically targeting CKR-L1. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Miptenalimab (BI-754111) is a monoclonal antibody targeting human LAG-3 with a dissociation constant (K_D) of 88.6 nM. This antibody effectively inhibits the interaction between LAG-3 and its physiological ligand MHC class II, highlighting its potential utility in modulating immune responses in oncological and immunological research.

Miromavimab (M777-16-3) is a monoclonal antibody specifically targeting the ectodomain epitope G-II of the rabies virus strain ERAGP. This antibody is designed for precise binding and neutralization of the rabies virus, making it an essential tool for research in virology and infectious diseases.

The Anti-RGMC/HFE2 Antibody (DISC-0974) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting RGMC/HFE2. This antibody is composed of a human IgG1 heavy chain and a kappa light chain, with a predicted molecular weight of 145.66 kDa. For isotype control purposes, reference should be made to the Human IgG1 kappa Isotype Control. This antibody is suitable for a range of research applications, focusing on the study of RGMC/HFE2 function and expression.

Levilimab (BCD-089) is a fully humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6R), playing a crucial role in the modulation of inflammatory responses. This antibody is specifically designed for the study of inflammatory diseases, including rheumatoid arthritis, where IL-6R-mediated signaling is implicated in disease pathology and progression. Levilimab provides a valuable tool for researchers investigating the therapeutic potential of IL-6R inhibition in inflammation and autoimmune disorders.

Lodelcizumab is a monoclonal antibody that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is utilized in research settings to investigate the biological mechanisms and potential therapeutic interventions for hypercholesterolemia. Lodelcizumab binds to PCSK9, inhibiting its function, which is crucial in the regulation of cholesterol levels in the bloodstream. This makes it a valuable tool for studies focused on lipid metabolism and cardiovascular disease.

Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody, engineered with high binding affinity and produced in CHO cells. This antibody effectively blocks the interaction between the MERS-CoV spike protein and the DPP4 receptor, thereby inhibiting the virus's entry into host cells. It is an essential tool for research focused on the molecular mechanisms of MERS-CoV infection and potential therapeutic interventions.

Tanezumab (RN-624) is a humanized monoclonal antibody that exhibits high affinity and specificity for nerve growth factor (NGF). By effectively blocking the interaction of NGF with its receptors, p75 and TrkA, Tanezumab modulates pain signaling pathways in the peripheral nervous system. This antibody is utilized extensively in research focused on both acute and chronic pain conditions, including osteoarthritis, knee pain, neuralgia, and post-herpetic neuralgia, providing a valuable tool for the study of pain mechanisms and therapeutic interventions.

Anivovetmab (KIND-030) is a monoclonal antibody of the IgG2 subtype, specifically targeting the VP2 protein, a major capsid protein of the canine parvovirus. This antibody is designed for the investigation of canine parvovirus infections, providing a critical tool for research into the pathogenesis and immune response to this virus. Anivovetmab is instrumental in advancing our understanding of viral mechanisms and potential therapeutic interventions for canine parvovirus.

The Anti-GAD65 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the GAD65 enzyme. This antibody features a human IgG1 heavy chain and a human lambda light chain, with a predicted molecular weight of 146.48 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for research focused on the enzymatic function and regulation of GAD65, particularly in studies related to its role in neurological and autoimmune disorders.

Flotetuzumab (MGD006; S80880) is a bispecific dual-affinity retargeting antibody (DART) that targets CD123 and CD3, designed for the treatment of acute myeloid leukemia (AML). This investigational molecule facilitates T-cell activation by concurrently engaging CD123 on target cells and CD3 on effector T cells. This interaction promotes T-cell-mediated cytotoxicity against the target cells. Efficacy studies, including those using a mouse model with patient-derived xenografts (PDX), have demonstrated flotetuzumab's potential to inhibit the progression of AML.

Cudarolimab (IBI101) is a fully human monoclonal antibody that targets OX40 (CD134), a costimulatory molecule predominantly expressed on activated immune cells. By inhibiting the interaction between OX40 and its ligand OX40L, Cudarolimab effectively modulates immune responses. This antibody demonstrates significant antitumor activity, making it particularly useful in cancer research studies.

CC-90002 is a humanized monoclonal antibody targeting CD47 with high specificity and subnanomolar affinity, evidenced by its dissociation constant (Kd). This antibody is designed for advanced studies in both hematologic malignancies and solid tumors, providing a critical tool for research in cancer therapy mechanisms and potential therapeutic interventions.

Pegrizeprument is a chimeric antibody of the Fab'-G1 -κ type, specifically targeting the CD28 receptor. This antibody is designed for high specificity and affinity in binding to the CD28 molecule, a critical co-stimulatory receptor involved in T-cell activation and survival. Pegrizeprument's unique structure and targeting capability make it an essential tool for research in immunology, particularly in studies related to T-cell function and immune response regulation.

Detumomab is a mouse-derived monoclonal antibody specifically designed to target human B-cell lymphoma. This antibody is particularly useful in the study of various cancers, including non-Hodgkin's lymphoma (NHL), providing essential insights into disease mechanisms and potential therapeutic targets.

Cizutamig is a dimeric humanized antibody that specifically targets TNFRSF17. It is constructed with a light chain kappa and heavy gamma 1 chain variable region, featuring a VH-G1 (CH1-h) configuration. This antibody is designed for high specificity and affinity in applications involving TNFRSF17 interaction studies.

Falbikitug is a humanized IgG1-kappa monoclonal antibody targeting leukemia inhibitory factor (LIF). Classified as an antineoplastic agent, Falbikitug is designed for therapeutic applications in oncology, specifically targeting and neutralizing LIF to inhibit tumor growth and progression. This antibody may be utilized in research studies to explore the role of LIF in cancer biology and to assess its potential as a therapeutic target in various malignancies.

Bimagrumab is a human monoclonal antibody designed to inhibit the activin type II receptor (ActRII), demonstrating high affinity with dissociation constants (KDs) of 1.7 pM for ActRIIB and 434 pM for ActRIIA. This specificity suggests its utility in investigating the mechanisms underlying pathological muscle loss and weakness. Bimagrumab serves as an essential tool for research focused on muscle degenerative diseases by targeting and modulating the signaling pathways involved in muscle growth and repair.

Afelimomab (MAK 195F) is a monoclonal antibody fragment, specifically an F(ab')2 fragment, targeting tumor necrosis factor (TNF). This antibody fragment is utilized primarily in the study of sepsis, offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions for this condition.

Tefibazumab is a humanized IgG1κ monoclonal antibody specifically designed to target and bind to clumping factor A, a surface-expressed adhesion protein. This antibody is utilized primarily in the study of serious infections caused by Staphylococcus aureus, offering a valuable tool for research in microbial pathogenesis and immune response mechanisms.

GEN-1053 (BNT-313) is a fully human monoclonal antibody of the IgG1 subclass, specifically targeting CD27. Upon binding to its antigen, GEN-1053 facilitates the formation of a hexameric structure. For experimental control purposes, Human IgG1 lambda1 serves as the appropriate isotype control for GEN-1053. This antibody is crucial for studies focusing on the modulation of the CD27 signaling pathway, which is significant in immune regulation and has implications in therapeutic interventions for immune disorders and cancers.

Tebentafusp (IMCgp100) is a bispecific fusion protein designed to specifically target the gp100 peptide-HLA-A*02:01 complex, an antigen commonly associated with melanoma. This innovative therapeutic agent employs a dual-action mechanism: it features a high-affinity T-cell receptor (TCR) binding domain that recognizes and binds to gp100-expressing tumor cells, coupled with an anti-CD3 T-cell engaging domain that recruits and activates T cells. Upon engagement, Tebentafusp mediates the production of inflammatory cytokines and cytolytic proteins, culminating in the direct lysis of tumor cells. This targeted approach not only enhances the specificity of T-cell mediated tumor cell killing but also minimizes off-target effects, making it a promising candidate for melanoma therapy.